184 related articles for article (PubMed ID: 12904142)
1. A safety look at currently available statins.
Moghadasian MH
Expert Opin Drug Saf; 2002 Sep; 1(3):269-74. PubMed ID: 12904142
[TBL] [Abstract][Full Text] [Related]
2. Statin treatment and the natural history of atherosclerotic-related diseases: pathogenic mechanisms and the risk-benefit profile.
Napoli C; Sica V
Curr Pharm Des; 2004; 10(4):425-32. PubMed ID: 14965203
[TBL] [Abstract][Full Text] [Related]
3. Statin-drug interactions: not a class effect.
Frishman WH; Horn J
Cardiol Rev; 2008; 16(4):205-12. PubMed ID: 18562811
[TBL] [Abstract][Full Text] [Related]
4. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Kostapanos MS; Milionis HJ; Elisaf MS
Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
[TBL] [Abstract][Full Text] [Related]
5. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
6. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
7. [Safety profile of statins].
Prieto JC
Rev Med Chil; 2001 Nov; 129(11):1237-40. PubMed ID: 11836874
[TBL] [Abstract][Full Text] [Related]
8. Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors.
Duplaga BA
Ann Pharmacother; 1999 Nov; 33(11):1224-7. PubMed ID: 10573325
[TBL] [Abstract][Full Text] [Related]
9. Safety considerations for statins.
Bolego C; Baetta R; Bellosta S; Corsini A; Paoletti R
Curr Opin Lipidol; 2002 Dec; 13(6):637-44. PubMed ID: 12441888
[TBL] [Abstract][Full Text] [Related]
10. The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered?
Jacobson TA
Mayo Clin Proc; 2006 Sep; 81(9):1225-31. PubMed ID: 16970219
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Williams D; Feely J
Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
[TBL] [Abstract][Full Text] [Related]
12. The myotoxicity of statins.
Evans M; Rees A
Curr Opin Lipidol; 2002 Aug; 13(4):415-20. PubMed ID: 12151857
[TBL] [Abstract][Full Text] [Related]
13. [Adverse effects of statins].
Andréjak M; Gras V; Massy ZA; Caron J
Therapie; 2003; 58(1):77-83. PubMed ID: 12822204
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of statins and exercise combination therapy compared to statin monotherapy in patients with dyslipidaemia: A systematic review and meta-analysis.
Gui YJ; Liao CX; Liu Q; Guo Y; Yang T; Chen JY; Wang YT; Hu JH; Xu DY
Eur J Prev Cardiol; 2017 Jun; 24(9):907-916. PubMed ID: 28436720
[TBL] [Abstract][Full Text] [Related]
15. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase.
Edwards IR; Star K; Kiuru A
Drug Saf; 2007; 30(6):515-25. PubMed ID: 17536877
[TBL] [Abstract][Full Text] [Related]
16. Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study.
Golomb BA; Kwon EK; Koperski S; Evans MA
Drug Saf; 2009; 32(8):649-61. PubMed ID: 19591530
[TBL] [Abstract][Full Text] [Related]
17. Long-term statin safety and efficacy in secondary prevention: can combination therapy improve outcomes?
Wascher TC
Atheroscler Suppl; 2003 Dec; 4(5):11-6. PubMed ID: 14980230
[TBL] [Abstract][Full Text] [Related]
18. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
Evans M; Rees A
Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559
[TBL] [Abstract][Full Text] [Related]
19. Statin therapy in the elderly.
Mungall MM; Gaw A
Curr Opin Lipidol; 2004 Aug; 15(4):453-7. PubMed ID: 15243219
[TBL] [Abstract][Full Text] [Related]
20. Safety review of combination drugs for hyperlipidemia.
Farnier M
Expert Opin Drug Saf; 2011 May; 10(3):363-71. PubMed ID: 21417957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
